Related Experiment Video

Updated: Mar 30, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]

P Ivanyi1, V Grünwald1

  • 1Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover.

Aktuelle Urologie
|November 12, 2015
PubMed

Insights

Targeted therapies have improved metastatic renal cell carcinoma (mRCC) treatment, but choosing the best drug remains challenging. Novel immunotherapies represent the next frontier in mRCC management, with promising trial results anticipated soon.

Area of Science:

  • Oncology
  • Medical Therapeutics

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has advanced significantly with targeted therapies.
  • Seven molecular targeted agents are currently approved for mRCC systemic treatment.
  • Individualized patient parameters and clinical data complicate optimal drug selection.

Purpose of the Study:

  • To review current therapeutic agents for mRCC.
  • To highlight the challenges in selecting the most appropriate targeted therapy.
  • To introduce novel immunotherapeutic approaches as the next stage in mRCC treatment.

Main Methods:

  • Review of current literature on mRCC systemic treatments.
  • Analysis of available molecular targeted agents and their clinical application.
  • Discussion of emerging immunotherapeutic strategies.

Main Results:

  • Targeted therapies have improved outcomes in mRCC over the past decade.
  • Despite advancements, selecting the optimal targeted agent remains a clinical challenge.
  • Novel immunotherapies are emerging as a promising next-generation treatment for mRCC.

Conclusions:

  • While targeted therapies have advanced mRCC care, challenges in treatment selection persist.
  • Immunotherapy represents a significant and promising new direction for mRCC treatment.
  • Further clinical trials are essential to optimize novel immunotherapeutic strategies for mRCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
621
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
781